Edgewise Therapeutics Stock Performance
| EWTX Stock | USD 32.08 0.10 0.31% |
Edgewise Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.93, which means possible diversification benefits within a given portfolio. Edgewise Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Edgewise Therapeutics is expected to follow. Use Edgewise Therapeutics downside variance, and the relationship between the total risk alpha and daily balance of power , to analyze future returns on Edgewise Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Edgewise Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Edgewise Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.37 | Five Day Return (1.56) | Year To Date Return 192.73 | Ten Year Return 7.33 | All Time Return 7.33 |
1 | OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc | 09/18/2024 |
2 | Disposition of 20922 shares by John Moore of Edgewise Therapeutics at 27.6295 subject to Rule 16b-3 | 09/23/2024 |
3 | Edgewise Therapeutics CMO sells 202k in company stock | 09/25/2024 |
4 | Analysts Think Theres Still Time To Get In On Edgewise | 09/30/2024 |
5 | Edgewise Therapeutics to Present on Sevasemten for Becker Muscular Dystrophy at the 29th International Annual Congress of the World Muscle Society | 10/01/2024 |
6 | Edgewise Therapeutics Insiders Sold US2.6m Of Shares Suggesting Hesitancy | 10/04/2024 |
7 | Acquisition by Carruthers R Michael of 70000 shares of Edgewise Therapeutics at 0.71 subject to Rule 16b-3 | 10/11/2024 |
8 | Acquisition by Behrad Derakhshan of 4800 shares of Edgewise Therapeutics at 1.93 subject to Rule 16b-3 | 10/25/2024 |
9 | Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - StockTitan | 11/07/2024 |
10 | Orbimed Advisors LLC Adjusts Stake in Edgewise Therapeutics Inc | 11/13/2024 |
11 | Edgewise Therapeutics shares get Outperform rating from Evercore ISI on potential | 11/22/2024 |
| Begin Period Cash Flow | 22 M | |
| Free Cash Flow | -97.7 M |
Edgewise |
Edgewise Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,875 in Edgewise Therapeutics on August 30, 2024 and sell it today you would earn a total of 1,345 from holding Edgewise Therapeutics or generate 71.73% return on investment over 90 days. Edgewise Therapeutics is currently generating 1.0912% in daily expected returns and assumes 7.6595% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Edgewise, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Edgewise Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edgewise Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edgewise Therapeutics, and traders can use it to determine the average amount a Edgewise Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1425
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EWTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.66 actual daily | 68 68% of assets are less volatile |
Expected Return
| 1.09 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Edgewise Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edgewise Therapeutics by adding it to a well-diversified portfolio.
Edgewise Therapeutics Fundamentals Growth
Edgewise Stock prices reflect investors' perceptions of the future prospects and financial health of Edgewise Therapeutics, and Edgewise Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edgewise Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 2.56 B | ||||
| Shares Outstanding | 94.69 M | ||||
| Price To Earning | 3.45 X | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (112.81 M) | ||||
| Net Income | (100.16 M) | ||||
| Cash And Equivalents | 248.4 M | ||||
| Cash Per Share | 4.99 X | ||||
| Total Debt | 5.41 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.49 X | ||||
| Book Value Per Share | 5.18 X | ||||
| Cash Flow From Operations | (91.95 M) | ||||
| Earnings Per Share | (1.50) X | ||||
| Market Capitalization | 3.05 B | ||||
| Total Asset | 340.04 M | ||||
| Retained Earnings | (244.76 M) | ||||
| Working Capital | 310.23 M | ||||
About Edgewise Therapeutics Performance
Evaluating Edgewise Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Edgewise Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edgewise Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.31) | (0.30) |
Things to note about Edgewise Therapeutics performance evaluation
Checking the ongoing alerts about Edgewise Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edgewise Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edgewise Therapeutics is way too risky over 90 days horizon | |
| Edgewise Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (100.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Edgewise Therapeutics currently holds about 248.4 M in cash with (91.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99. | |
| Edgewise Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Edgewise Therapeutics shares get Outperform rating from Evercore ISI on potential |
- Analyzing Edgewise Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edgewise Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Edgewise Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edgewise Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edgewise Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edgewise Therapeutics' stock. These opinions can provide insight into Edgewise Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.